Company HighlightsEvent
February 22, 2024

Road to DCAT Week 2024

ICE Pharma is happy to announce our participation in DCAT Week 2024! As pioneers in bile acid research, we’re eager to showcase our groundbreaking work and connect with industry...

ArticlesCompany Highlights
February 1, 2024

Lithocholic acid (LCA) is enriched in the microbiome of centenarians

The centenarian’s riddle explores the keys to longevity.  Many scientists estimate longevity is based 20% on genetics, with 80% determined by your lifestyle choices and environment, but for some...

ArticlesCompany Highlights
January 10, 2024

Ursodeoxycholic acid improves outcomes in liver diseases

Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years (DALYs) in the total population. The global burden of CLD is increasing globally. Although screening,...

ArticlesCompany Highlights
January 5, 2024

The potential of bile acids as anti-COVID-19 therapies

Professor Stefano Fiorucci, member of ICE Pharma’s Scientific Advisory Board, and his colleagues, examined how the potential of bile acids as anti-COVID-19 therapies. Preventing SARS-CoV-2 infection by modulating viral host...

Company HighlightsEvent
December 4, 2023

ICE Pharma attended CPHI India 2023

ICE Pharma attended the main pharma industry exhibition Southeast Asia, CPHI India, which was held in Delhi from 28 – 30 of November. We would like to thank our...

Company HighlightsInsights
November 17, 2023

Bile acids – Thyroid hormone activation

Bile acids are important metabolic messengers. Modifications in BA abundance or signalling are associated with metabolic diseases including obesity, type 2diabetes, non-alcoholic steatohepatitis and atherosclerosis. Bile acids have long...

Company HighlightsEvent
November 2, 2023

ICE Pharma attended CPHI Barcelona 2023

ICE Pharma attended the main pharma industry exhibition of 2023, CPHI, which was held in Barcelona from 24 to 26 of October. During the three days event, we had...

Company HighlightsInsights
October 17, 2023

ICE Pharma will join the fourth edition of the initiative “Fabbriche Aperte” organized by the Piedmont Region

ICE Pharma will join the fourth edition of the initiative “Fabbriche Aperte” organized by the Piedmont Region, which will take place in our production site of Basaluzzo on October...

Company HighlightsInsights
September 28, 2023

ICE Pharma will develop a 100% recyclable booth at CPHI Barcelona 2023

Actions speak louder than words. Through robust processes, continuous improvements, and substantial investments in materials, we are committed to reduce our environmental footprint and enhance energy efficiency, minimizing our...

Company HighlightsNZP
September 1, 2023

New Zealand Pharmaceuticals is the new principal front of jersey partner of the Manawatū Cyclones

NZP is excited to announce the sponsorship of the Manawatū Cyclones, the local female rugby team. The sport of rugby has profoundly impacted the national identity and cultural fabric...

Company HighlightsEvent
July 4, 2023

ICE Pharma attended EASL congress 2023

It was a great pleasure to share with you our wealth of experience, work and passion. An inspiring opportunity to meet, listen and discuss recent advances from the EASL Conference which...

Company HighlightsICEJapan
May 24, 2023

ICE Pharma celebrated the first-year anniversary of its acquisition of the UDCA plant in Iwaki

The group has done an incredible job in completing the integration and establishing a new organisation in less than one year, as well as establishing good relationships with local...